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Using meta-regression analyses in addition
to conventional systematic review methods
to examine the variation in cost-
effectiveness results – a case study
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Abstract
Background: Systematic reviews of cost-effectiveness analyses summarize results and describe study characteristics.
Variability in the study results is often explained qualitatively or based on sensitivity analyses of individual studies.
However, variability due to input parameters and study characteristics (e.g., funding or study quality) is often not
statistically explained. As a case study, a systematic review on the cost-effectiveness of drug-eluting stents (DES)
versus bare-metal stents (BMS) using meta-regression analyses is performed to explore the usefulness of such
methods compared with conventional review methods.
Methods: We attempted to identify and review all modelling studies published until January 2012 that compared
costs and consequences of DES versus BMS. We extracted general study information (e.g., funding), modelling
methods, values of input parameters, and quality of the model using the Philips et al. checklist. Associations
between study characteristics and the incremental costs and effectiveness of individual analyses were explored
using regression analyses corrected for study ID.
Results: Sixteen eligible studies were identified, with a combined total of 508 analyses. The overall quality of the
models was moderate (59 % ± 15 %). This study showed associations (e.g., type of lesion) that were expected
(based on individual studies), however the meta-regression analyses revealed also unpredicted associations: e.g.,
model quality was negatively associated with repeat revascularizations avoided.
Conclusions: Meta-regressions can be of added value, identifying significant associations that could not be
identified using conventional review methods or by sensitivity analyses of individual studies. Furthermore, this study
underlines the need to examine input parameters and perform a quality check of studies when interpreting the
results.
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Background
Economic evaluations are increasingly used to assist in
decision making of interventions. Often for a specific
decision problem different economic evaluations are
conducted. The results of these studies may differ sub-
stantially between studies: from interventions being
dominated to being dominant. Therefore, it is necessary
that systematic reviews are performed to summarize the
results of the individual economic evaluations. Besides
summarizing the study characteristics and results it
would be interesting to explain statistically the variability
in the incremental costs and incremental effects and
thus the conclusions. Differences can exist due to differ-
ences in values used for input parameters, perspective,
time horizon and other factors. Some differences could
easily be explained by the values that were used for the
input parameters, since for some input parameters a
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Table 1 Description economic evaluations
Study Year Country # Analyses Horizon
(months)
Model Fundingb Subgroups Comparison Price
per stent
(2012 €)
Price
difference
DES vs BMS
(2012 €)
# Stents
per procedure
Quality
(%)a
Ekman et
al. [15]
2004 Sweden 66 12,24 DT Yes High risk,
diabetes, type
of lesion, type
of vessel
BMS vs NS 1.1-1.8 41
PES NS 693-1271
Hill et al.
[22]
2004 UK 36 12-60 STM No High risk,
# vessels
BMS vs 679 1.3,2.4 77
DES 1607 929
Tarricone et
al. [19]
2004 Italy 10 12 DT Yes # vessels,
diabetes, type
of lesion, type
of vessel
BMS vs NS 1.2 – 2.6 46
SES NS 0
Bowen et
al. [21]
2005 Canada 50 12 DT No Post MI,
diabetes, type
of lesion
BMS vs 531 1.23–2.26 61
DES 1681 1150
Mittmann
et al. [13]
2005 Canada 8 12 DT NS BMS vs 522 1.5 50
SES 2062 1540
PES 2062 1540
Shrive et al.
[17]
2005 Canada 11 LT STM Yes Diabetes, age BMS vs 430 1.05–1.75 56
SES 1246-
3114
816-2685
Mahieu et
al. [12]
2006 Belgium 31 12 DT NS Diabetes, type
of lesion, type
of vessel
BMS vs NS 1 32
SES NS 731-1306
PES NS 731-1306
Hill et al. [2] 2007 UK 172 12 STM No High risk,
elective
BMS vs 485 1-2 80
SES 1700-
1774
1215-1289
PES 1621-
1696
1136-1211
Kuukasjarvi
et al. [23]
2007 Finland 2 24 DT No BMS vs NS NS 33
DES NS NS
Neyt et al.
[8]
2007 Belgium 59 12 DT NS Diabetes, #
vessels, type
of lesion
BMS vs 553-
1106
1.09–1.97 72
DES 553-
1659
0-1106
Polanczyk
et al. [18]
2007 Brazil 4 12, LT STM Yes BMS vs 831-
1390
1.2 56
SES 3169 1779, 2337
Bischof et
al. [14]
2009 USA 4 36 STM No BMS vs NS NS NS 76
SES NS
PES NS
Goeree et
al.[24]
2009 Canada 45 24 DT No Diabetes, type
of lesion, type
of vessel
BMS vs 470 1.1–2.37 52
DES 1486 391-1016
Ferreira et
al. [16]
2010 Brazil 1 26 DT No BMS vs 1883 NS 36
PES 5272 3390
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linear relationship with the outcomes exists. For ex-
ample, an increase in initial intervention costs will lead
to an increase in the incremental costs, ceteris paribus.
Often these variations are explained by sensitivity ana-
lyses of individual studies. Other associations with input
parameters that do not have a linear association with the
outcome (e.g., probabilities leading to changes in costs
and effects) or study characteristics (e.g., funding) could
be identified using meta-regression analyses in addition
to conventional systematic review methods. Meta-
regression analyses are currently used to combine the re-
sults of clinical trials and to investigate the effect of
methodological diversity of the studies on the results
[1]. To explain the variability in the incremental costs
and incremental effects of cost-effectiveness analysis
(CEA) it could be useful to apply these meta-
regression analyses in systematic reviews of economic
evaluations.
The aim of this study is to explore the usefulness of
meta-regression analyses in systematically explaining the
variability in the results compared with conventional re-
view methods and sensitivity analyses of individual stud-
ies. Meta-regression analyses may be useful if they
provide more information, in terms of associations with
the outcomes, than conventional systematic reviews and
sensitivity analyses. Many economic evaluations have es-
timated the cost-effectiveness of drug-eluting stents
(DES) versus bare-metal stents (BMS) for the treatment
of patients with coronary artery disease. The results be-
tween the studies vary considerably, which makes this
decision problem a good case study to explore if meta-
regression analyses are of added value. Systematic re-
views [2–4] on the cost-effectiveness of DES versus BMS
have been performed but did not explore statistically the
causes of the variability in incremental costs and incre-
mental effects between the studies. Associations with the
incremental outcomes (costs, quality-adjusted life years
and repeat revascularizations avoided) will be identified
in this study. Besides the ‘known’ factors (e.g., age, type
of lesion, price of stents, relative risk repeat revasculari-
sations avoided) explaining the cost-effectiveness of DES
versus BMS we will identify associations that could only
be identified at a meta-level such as the quality of the
studies and funding.
Methods
Inclusion and exclusion criteria
A systematic literature search was performed to identify
all English-language (online or print) publications (at
any time before January 2012) of CEAs using decision
analytic models to compare the costs and consequences
of DES (sirolimus-eluting stent (SES), paclitaxel-eluting
stent (PES), everolimus or zotarolimus-eluting stent
(ZES)) versus BMS for patients who require a stent im-
plantation due to an atherosclerotic lesion of the coron-
ary artery. The effectiveness of the studies had to be
expressed in quality adjusted life years (QALY) or in dis-
ease specific measures such as repeat revascularizations
avoided, TLR (target lesion revascularization) and TVR
(target vessel revascularization). Furthermore, studies
were only included if they reported results in enough de-
tail to enable separation of incremental costs from incre-
mental effects. There was no restriction on the
perspective used in the economic evaluation. Reviews,
editorials and abstracts were not included in the review.
Studies were identified using electronic databases
(PubMed, EMbase, NHS EED, Cochrane Library and
INAHTA) and by scanning reference lists of eligible arti-
cles. The full search strategies for EMbase and PubMed
are presented in Additional file 1. To ensure that all
relevant publications were identified in the CRD (NHS
EED and HTA) and Cochrane Library databases we lim-
ited the search terms to “stent” and “stents”. These
terms were searched in “any field” for CRD and in “title,
abstract, keywords” for Cochrane Library. We also in-
cluded the relevant publications found in the reviews by
Ligthart et al. [4], Hill et al. [2], and Neyt et al. [3].
Data extraction
One reviewer (LB) screened the titles and abstracts iden-
tified through the searches. The full text evaluation was
performed by two reviewers (LB & FW) and discrepan-
cies were discussed and resolved by consensus or by
consulting a third reviewer (WR). Various parameters
(Tables 1 and 3) were extracted from the relevant publi-
cations by one reviewer (LB). The parameters chosen in
the regression analyses were the most likely general
study characteristics (e.g., population, time horizon,
funding) that are reported in conventional systematic
Table 1 Description economic evaluations (Continued)
Jahn et al.
[10, 11]
2010 Austria 6 84 DES No Diabetes, type
of lesion
BMS vs NS 1.24 47
DES NS NS
Remak et
al. [20]
2010 UK 3 48 STM Yes BMS vs 433 1.11 62
ZES 1175 742 1.12-1.4
a Philips checklist 2006: scale 0-100 %
b Yes: manufacturer; No: funded by government or not funded
DES discrete event simulation, DT decision tree, LT life time, vs versus, MI myocardial infarction, NS not stated, STM state-transition model, # vessels number of
vessels treated
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reviews. In addition, we added the most important input
parameters (e.g., cost of procedure, relative risk of repeat
revascularization, probability of repeat revascularization,
utilities) that are used in the model to estimate the cost-
effectiveness. These key parameters are often varied in
deterministic sensitivity analyses. Costs were converted
to Euros [5] and corrected for inflation if necessary [6]
to present the costs as 2012 Euros. Furthermore, we
wanted to see if modelling assumptions (e.g., oculo-
stenotic effect) were of influence on the incremental
Fig. 1 Flow of studies through the review process. PES: paclitaxel eluting stent; SES: sirolimus eluting stent; ZES: zotarolimus eluting stent; DES:
drug eluting stent
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outcomes. All assumptions reported in the studies were
monitored. Lastly, two reviewers (LB & FW) independ-
ently assessed the quality of the models using the Philips
et al. checklist [7] for the assessment of model-based
economic analyses. The Philips checklist is a framework
based on existing guidelines on the use of decision ana-
lytic modelling in health technology assessments. The
checklist is structured in three themes: a) structure,
which focusses on the scope and mathematical structure;
b) data, which examines data identification and uncer-
tainty methods; and c) consistency, which assesses the
overall quality of the model based on the publication.
Both overall study quality and the quality per theme
were given a score from 0-100 %, which was calculated
by dividing the sum of the questions answered positively
by the total number of relevant questions. Since some
questions were not relevant for all studies (e.g., ques-
tions concerning quality-of-life values) the denominator
could differ between studies.
Analysis
The influence of modelling methods, the choice of pa-
rameters and the quality of the models on the main out-
comes (incremental costs, incremental QALYs and
absolute risk reduction repeat revascularizations) were
analysed both quantitatively and qualitatively.
Associations between parameters and the outcomes
were assessed by identifying outliers found on cost-
effectiveness planes. Furthermore, several bivariate linear
regressions were estimated to confirm the associations
and also to measure the influence of other parameters
on the outcomes. Including associations that could be
predicted beforehand (e.g., type of lesion, price stent) are
included in the regression analyses since it could be seen
as a validation check if the analyses also show these as-
sociations. Multivariate analyses with all of the parame-
ters that were significant in the bivariate analyses could
not be performed due to a high frequency of missing
values caused by incomplete reporting.
We included every subgroup or sensitivity analysis
found in a study as long as incremental costs or incre-
mental effectiveness were provided or could be calcu-
lated. As a result, our meta-regression analyses were
based on many more observations than the number of
studies that were included. Since Hill et al. [2] provided
more than 30 % of the observations used in our study;
we incorporated study ID as a random effect in the re-
gression models. Some studies reported both incremen-
tal effects and incremental QALYs for a specific analysis.
Since the incremental costs associated with both out-
comes is the same we only included one of the two ana-
lyses for the regression analyses on the incremental
Fig. 2 Cost-effectiveness plane, repeat revascularizations avoided
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costs to avoid double counting. Data management and
all statistical analyses were performed with SPSS 19.0
(SPSS Inc., Chicago, IL, USA). The level of measurement
was ordinal or ratio, depending on the covariate. The
model assumptions and study characteristics (e.g., fund-
ing) were measured at an ordinal scale. Input parameters
such as the probability of repeat revascularization were
measured at a ratio scale. Conclusions about statistical
significant were based on an alpha level of 5 %.
Results
Figure 1 presents the process of identifying relevant publi-
cations in line with PRISMA guidelines (Additional file 2).
Of the 1957 potentially relevant publications, 1872 were
excluded based on title, abstract and keywords. Full-text
evaluation was performed for 85 articles leading to 18
relevant studies. Reasons to exclude studies after a full text
assessment were: lack of a model (n = 24), no original
CEA (n = 22), language other than English (n = 8), no rele-
vant outcome (n = 6), comparator not BMS (n = 4), and re-
sults were not presented at a disaggregated level (n = 3). In
one case, we found that a full report [8] and a paper [9]
reported results from the same analyses; data was there-
fore extracted from the full report. In another case, we
found two papers with the same content and results and
considered them as one paper [10, 11].
The 16 eligible studies were divided into five groups
based on the type of DES that was evaluated and
accounted for 498 separate analyses (Table 1). Four stud-
ies calculated the incremental cost-effectiveness ratio
(ICER) for both PES and SES [2, 12–14], two studies
[15, 16] focused on PES, three studies focused only on
SES [17–19], and one study used ZES as the intervention
[20]. The remaining six publications [8, 10, 11, 21–24] did
not specifically identify the type of eluting drug under
evaluation and calculated an ICER for a DES in general,
Descriptive characteristics
In most analyses, DES was more expensive (88 % of ana-
lyses) and more effective in both QALYs and repeat re-
vascularizations avoided (99 % of analyses) than BMS.
Most of the 16 studies [2, 8, 10, 11, 14, 16, 21, 23] con-
cluded that DES is not cost-effective for all subgroups
since the incremental QALYs did not offset the
Fig. 3 Cost-effectiveness plane, quality-adjusted life years gained. * The lines present the willingness to pay thresholds of 20,000 per QALY gained
and 30,000 per QALY gained. The threshold in the Netherlands is between 20,000 - 80,000 per QALY gained [32]
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incremental costs. However, many concluded that DES
was more cost-effective in high-risk patients. The ICER
varied considerably between and within studies: from
DES being dominated by BMS [14, 21] to DES being
dominant in specific analyses [2, 8, 10, 11, 15, 19, 22].
Figs. 2 and 3 present the variability of the incremental
costs and effects of the studies using repeat revasculari-
zations avoided or QALYs as an outcome measure, re-
spectively. The mean values of input parameters
stratified by the type of study outcome are presented in
Table 2.
We also assessed the quality of the models of all stud-
ies using the Philips et al. [7] checklist. Studies appeared
to score higher on the theme structure (63 % ± 16 %)
than on the other two themes, data (57 % ± 22 %) and
consistency (55 % ± 21 %). The average overall quality of
the models was moderate (59 % ± 15 % of a maximum
possible score of 100 %).
Outcome repeat revascularizations avoided
Based on 124 separate analyses (9 studies), the num-
ber of repeat revascularizations avoided (the absolute
risk reduction in repeat revascularizations) with DES
also varied considerably (Fig. 2) between and within
studies (range: −0.0001, 0.19), which resulted in
variation in the ICERs. The overall conclusions of
most of the studies corresponded with the 124 separ-
ate analyses (Table 3). The regression analyses showed
that the relative risk reduction of repeat revasculariza-
tions and the initial probabilities of restenosis were
positively associated with repeat revascularizations
avoided. Furthermore, a more complex vessel or le-
sion was associated with higher relative risk reduction
and initial risk of restenosis after a percutaneous cor-
onary intervention with BMS. Consequently, this leads
to an increase in repeat revascularizations avoided
and DES becomes more effective. Furthermore, the
number of stents was also positively and significantly
associated with repeat revascularizations avoided,
probably because it is a proxy for subgroups who
have a higher risk of developing restenosis due to dia-
betes, lesions and vessels characteristics. These factors
could have been predicted beforehand since subgroup
analyses and sensitivity analyses of the individual
studies show the same conclusions.
Besides these factors that could be predicted before-
hand, with the meta-regression analyses we were able
to find a negative association between overall quality
of a model and repeat revascularizations avoided. Fur-
thermore, the theme data was also negatively
Table 2 Averages economic evaluations (univariate analyses)
Total (CEAs & CUAs) (N = 16) CEAs (N = 9) CUAs (N = 11)
Average ± SD Average ± SD Average ± SD
Incremental outcomes
Incremental costs €982 ± €894
Incremental QALYs 0.0042 ± 0.008
Incremental repeat revascularization avoided 0.0958 ± 0.0521
Input parameters
Number of stents per procedure 1.503 ± 0.367 1.382 ± 0.355 1.540 ± 0.364
Price of DES stent € 1,654 ± € 390 € 1,912 ± € 672 € 1,614 ± € 307
Price of BMS stent € 555 ± € 166 € 670 ± € 307 € 534 ± € 114
Price difference between stents € 1,085 ± € 337 € 1,189 ± € 336 € 1,056 ± € 331
Price of DES procedure (incl. stents) € 6,328 ± € 2,509 € 7,811 ± € 1,475 € 5,998 ± € 2,573
Price of BMS procedure (incl. stents) € 4,442 ± € 2,195 € 6,259 ± € 1,536 € 4,160 ± € 2,138
Cost difference between the procedures € 1,787 ± € 686 € 1,551 ± € 805 € 1,840 ± € 647
Probability restenosis BMS 0.142 ± 0.076 0.148 ± 0.055 0.140 ± 0.081
Probability restenosis DES 0.064 ± 0.038 0.056 ± 0.027 0.068 ± 0.041
Relative risk reduction DES vs. BMS 0.484 ± 0.204 0.578 ± 0.214 0.449 ± 0.189
Quality (0-100 %)*
Total 59.5 ± 15.4
Structure 62.5 ± 16.1
Data 56.7 ± 21.6
Consistency 55.1 ± 20.8
* N = 16 studies
CEA cost-effectiveness analysis, CUA cost-utility analysis
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Table 3 Associations between incremental revascularizations and covariates – DES vs BMSa
Bivariate
Δ Repeat revascularization d
Covariates β N se
120
Population
Age 70
Age >75 NA 0 NA
Age 65-75 −0.018 8 0.05
Age < 65 ref 62
Complex lesion (yes vs. no) 0.029* 56 0.007
Complex vessel (yes vs. no) 0.042* 27 0.012
Multi vessel disease (yes vs. no) 0.019* 12 0.007
Diabetes (yes vs. no) 0.02* 64 0.007
Post MI (yes vs. no) 0.007 25 0.011
Elective (yes vs. no) NA 0 NA
High risk (yes vs. no) NA 0 NA
Intervention
Type DES 120
Sirolimus eluting stent 0.102* 21 0.014
Paclitaxel eluting stent 0.063* 56 0.014
Zotarolimus eluting stent NA 0 NA
Drug eluting stent in general ref 43
Study characteristics
Country 120
Canada −0.099 42 0.056
Sweden −0.036 27 0.068
Brazil −0.08 5 0.072
Finland −0.04 1 0.072
Belgium −0.07 39 0.059
Italy ref 10
Study year 0.01 120 0.008
Horizon >1 year (yes vs. no) −0.006 120 0.021
Horizon (months) b <0.001
Type of study (CUA vs. CEA) NA NA NA
Model 120
Markov model NA 0 NA
Discrete event simulation model NA 0 NA
Decision tree NA 120 NA
Perspective 120
Health care provider perspective 0.004 6 0.017
Health care sector perspective 0.04 31 0.05
Non-public perspective NA 0 NA
Health care payer perspective ref 83
Funding 73
No 0.034 27 0.045
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associated with this incremental outcome. Conse-
quently, models with a higher quality led to less
favourable results for DES.
Outcome of incremental QALYs
Figure 3 presents the incremental QALYs and incremen-
tal costs for 384 separate cost-effectiveness analyses (11
Table 3 Associations between incremental revascularizations and covariates – DES vs BMSa (Continued)
Yes 46
Both Industry and No industry NA 0 NA
Industry 0.102* 37 0.046
No industry ref 9
Discounting (yes vs. no)c −0.084* 11 0.026
Input parameters
Number of stents used during the procedure 0.033* 111 0.01
Price difference between stents NA NA NA
Price of BMS stent NA NA NA
Price of DES stent NA NA NA
Costs of BMS procedure (incl. stents) NA NA NA
Costs of DES procedure (incl. stents) NA NA NA
Difference in procedure costs NA NA NA
Probability of restenosis BMS 0.521* 112 0.041
Probability of restenosis DES 0.436* 112 0.127
Relative risk reduction repeat revascularization 0.132* 112 0.018
Disutility of undergoing a CABG NA NA NA
Disutility of undergoing a PCI NA NA NA
Disutility of experiencing a MI NA NA NA
Disutility for a patient with angina symptoms NA NA NA
Quality of life of a patient with angina symptoms NA NA NA
Quality of life of a patient after revascularization (recovered) NA NA NA
Quality of life of a patient suffering from restenosis NA NA NA
Assumptions
Difference in clopidogrel (medication) usage (yes vs. no) 0.001 45 0.015
Wait time for revascularization included (yes vs. no) −0.051 77 0.048
Repeat revascularization is based on angiographic follow-up data (yes vs. no) 0.082* 82 0.01
DES and BMS are not mixed up during a procedure −0.061 120 0.047
Repeat interventions that occur during time horizon are the result of restenosis NA 120 NA
There do not exist differences in mortality, thrombosis or MI between DES and BMS 0.039 120 0.039
The type of repeat revascularization is the same for the DES and BMS treatment groups −0.071 120 0.044
There does not exist a difference in survival between DES and BMS 0.015 120 0.033
There does not exist a difference in thrombosis between DES and BMS 0.039 120 0.039
There does not exist a difference in MI between DES and BMS 0.046 120 0.031
Quality of studies (Philips et al. 2006) [7]
Structure (%) −0.145 120 0.099
Data (%) −0.167* 120 0.066
Consistency (%) −0.153 120 0.081
Total (%) −0.250* 120 0.087
a Corrected for study; bShrive et al. & Remak et al. [17, 20] not included (lifetime horizon); c only studies with a time horizon longer than 1 year included;
dincremental repeat revascularization avoided; *p value < 0.05
CEA cost effectiveness analysis, CUA cost utility analysis, DES drug eluting stent, MI myocardial infarction, NA not applicable, BMS bare metal stent, CABG coronary
artery bypass graft, DES drug eluting stent, MI myocardial infarction, NA not applicable, PCI percutaneous coronary intervention
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studies). This Figure shows that Shrive et al. [17] and
Remak et al. [20] clearly found a larger incremental
QALY gain than the other studies.
Again, the meta-regression analyses found associations
with incremental QALYs that were expected (Table 4).
Relative risk reduction of repeat revascularizations and
the initial probability of restenosis after BMS were asso-
ciated with a greater QALY gain, as seen in individual
sensitivity analyses [2, 14, 15, 21, 22, 24]. Furthermore,
analyses showed that non-elective patients, patients with
a high risk of a repeat revascularization, patients with
complex vessels or lesions or older patients will benefit
more from DES, something that was also recognised in
the individual studies [2, 12, 17, 21, 24]. In addition, we
found a significant positive association between time
horizon (continuous) and incremental QALYs. This was
also found by Hill et al. [22] and Ekman et al. [15] who
varied the time horizon in the sensitivity analyses.
Studies [2, 17] that have explicitly mentioned that they
have assumed that the occurrence of repeat revasculari-
zations within the time horizon is the result of restenosis
and studies assuming that repeat revascularization rates
are based on angiographic follow-up have estimated sig-
nificantly higher incremental QALYs. Angiographic
follow-up leads to inflated estimates of clinical effective-
ness compared with clinical follow-up since not clinically
significant restenosis results in “unnecessary” repeat re-
vascularizations when angiographic follow-up is per-
formed. Consequently, the difference in repeat
revascularizations will be overestimated (oculo-stenotic
effect) [25]. Some studies use “real-world” [8, 10, 11, 21]
follow-up data and consequently report lower estimates
(visible in Figs. 2 and 3) than other studies such as, Remak
et al. [20] that used angiographic follow-up [12, 15, 17, 23].
This phenomenon is described earlier by Eisenberg et al.
[26], who concluded that cost-effectiveness studies using
angiographic follow-up overestimate the cost-effectiveness
of DES.
The meta-regression analyses showed that studies
using real-world evidence compared with angiographic
follow-up leads to a reduction in incremental QALY
gain. The added value of meta-regression analyses is lim-
ited in explaining the variation in incremental QALYs,
although it identified modelling assumptions that were
significantly associated with incremental QALYs.
Outcome incremental costs
Figures 2 and 3 show that there was large variation in
incremental costs (range: €-4070 to €3506). Regression
analyses (Table 5) confirmed associations (cost parame-
ters and population characteristics) that were seen in the
individual studies [2, 8, 12, 17, 20, 21, 24]. The analyses
showed that probability of restenosis after BMS, the re-
duction in restenosis risk by DES, the difference in stent
price, and the number of stents used were important pa-
rameters influencing the incremental costs. Both input
parameters varied considerably between the analyses: the
difference in stent costs ranged from €0 [8, 19] to €2685
[17] and the number of stents varied between 1 [22] and
2.6 [19] stents per procedure depending on the type of
patient.
On a meta-level we were able to conclude that funding
and the type of cost-effectiveness analysis was associated
with incremental costs. Funding was provided by the
stent manufacturer in five [15, 17–20] of the 16 studies
and three of them [15, 17, 20] concluded that DES was
cost-effective compared with BMS. Of the studies that
were not funded by a manufacturer (N = 8) only one [10,
11] of them concluded that DES could be cost-effective.
Studies that were not funded estimated on average
higher incremental costs than studies that were (p <
0.05). Furthermore, some associations with incremental
costs are recognised from scenario analyses performed
by studies. The directions of the following associations
are confirmed by the regression analysis but not signifi-
cant. According to Jahn et al. [10, 11] it is important to
incorporate wait time into the model since it leads to a
decrease (−734, 95 % CI:-1690;223) in incremental costs.
A time horizon shorter than 12 months was associated
with higher incremental costs (479, 95 % CI: −1024;65);
Hill et al. [22] estimated costs and effects for different
time horizons and showed that a longer time horizon
led to lower incremental costs. This is likely because of
the continuing treatment effect of DES in the subse-
quent years which would increase in the number of re-
peat revascularizations avoided compared with BMS.
This increase in reduction of repeat revascularization
would further offset the cost of the initially more expen-
sive DES.
Meta-regression analyses showed also that the number
of repeated revascularizations avoided explained a large
proportion of variation (R2 = 0.53). As shown in Fig. 2,
there appeared to be a linear association between incre-
mental costs and repeat revascularizations avoided. In-
cremental QALYs (Fig. 3), on the other hand, was not
associated with incremental costs (R2 = 0.001), probably
since incremental QALYs are determined by several fac-
tors including repeat revascularizations avoided, life-
years gained and quality of life values.
Discussion
This study explored the usefulness of meta-regression
analyses in combination with a systematic review of eco-
nomic evaluations compared with conventional review
methods. The aim of conventional systematic reviews is
to show relevant publications on the cost-effectiveness
of certain treatments in a systematic manner. When pos-
sible, conventional reviews describe associations between
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Table 4 Associations between incremental QALYs and covariates – DES vs BMSa
Bivariate
Δ QALYs
Covariates β N se
384
Population
Age 190
Age >75 0.029* 1 0.002
Age 65-75 0.015* 52 0.002
Age < 65 ref 137
Complex lesion (yes vs. no) 0.001* 123 <0.001
Complex vessel (yes vs. no) 0.001* 51 <0.001
Multi vessel disease (yes vs. no) 0.001 90 <0.001
Diabetes (yes vs. no) <0.001 135 <0.001
Post MI (yes vs. no) <0.001 25 0.001
Elective (yes vs. no) −0.001* 208 <0.001
High risk (yes vs. no) 0.004* 127 0.001
Intervention
Type DES 384
Sirolimus eluting stent 0.01 75 0.009
Paclitaxel eluting stent 0.011 151 0.009
Zotarolimus eluting stent 0.025 3 0.015
Drug eluting stent in general ref 155
Study characteristics
Country 384
United Kingdom 0.011 211 0.015
United States 0.001 4 0.019
Canada 0.016 72 0.015
Sweden 0.002 39 0.019
Austria 0.001 6 0.019
Finland 0.005 1 0.019
Belgium 51
Study year 0.001 384 0.002
Horizon >1 year (yes vs. no) 0.002 384 0.001
Horizon (months) b <0.001* 373 <0.001
Type of study (CUA vs. CEA) NA NA NA
Model 384
Markov model 0.014 226 0.008
Discrete event simulation model 0.001 6 0.014
Decision tree ref 152
Perspective 384
Health care provider perspective 0.006 7 0.012
Health care sector perspective NA 0 NA
Non-public perspective NA 0 NA
Health care payer perspective ref 377
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Table 4 Associations between incremental QALYs and covariates – DES vs BMSa (Continued)
Funding 333
No −0.001 30
Yes 303
Both Industry and No industry 0.043* 11 0.008
Industry 0.012 42 0.006
No industry ref 250
Discounting (yes vs. no)c 0.015 90 0.013
Input parameters
Number of stents used during the procedure 0.001 379 0
Price difference between stents NA NA NA
Price of BMS stent NA NA NA
Price of DES stent NA NA NA
Costs of BMS procedure (incl. stents) NA NA NA
Costs of DES procedure (incl. stents) NA NA NA
Difference in procedure costs NA NA NA
Probability of restenosis BMS 0.024* 366 0.001
Probability of restenosis DES 0.005 282 0.004
Relative risk reduction repeat revascularization 0.007* 300 0.001
Disutility of undergoing a CABG −0.747* 254 0.163
Disutility of undergoing a PCI −0.107 254 0.433
Disutility of experiencing a MI −0.021 40 0.097
Disutility for a patient with angina symptoms −0.012 78 0.013
Quality of life of a patient with angina symptoms −0.231* 338 0.04
Quality of life of a patient after revascularization (recovered) −0.24* 380 0.024
Quality of life of a patient suffering from restenosis −0.254* 144 0.031
Assumptions
Difference in clopidogrel (medication) usage (yes vs. no) <0.001 270 0.001
Wait time for revascularization included (yes vs. no) −0.012* 336 0.006
Repeat revascularization is based on angiographic follow-up data (yes vs. no) 0.013* 329 0.006
DES and BMS are not mixed up during a procedure 0.002 384 0.01
Repeat interventions that occur during time horizon are the result of restenosis 0.02* 384 0.01
There do not exist differences in mortality, thrombosis or MI between DES and BMS −0.003 384 0.016
The type of repeat revascularization is the same for the DES and BMS treatment groups −0.008 384 0.016
There does not exist a difference in survival between DES and BMS 0.001 384 0.002
There does not exist a difference in thrombosis between DES and BMS −0.003 384 0.016
There does not exist a difference in MI between DES and BMS −0.006 384 0.01
Quality of studies (Philips et al. 2006) [7]
Structure (%) −0.006 384 0.033
Data (%) 0.006 384 0.024
Consistency (%) −0.018 384 0.02
Total (%) <0.001 384 0.032
a Corrected for study; bShrive et al. & Remak et al. [17, 20] not included (lifetime horizon); c only studies with a time horizon longer than 1 year included;
* p value < 0.05
CEA cost effectiveness analysis, CUA cost utility analysis, DES drug eluting stent, MI myocardial infarction, NA not applicable, BMS bare metal stent, CABG coronary
artery bypass graft, DES drug eluting stent, MI myocardial infarction, NA not applicable, PCI percutaneous coronary intervention
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Table 5 Associations between incremental costs and covariates – DES vs BMSa
Bivariate
Δ Costs (2012€)
Covariates β N se
437
Population
Age 190
Age >75 315 1 901
Age 65-75 −31 52 695
Age < 65 ref 137
Complex lesion (yes vs. no) 172* 134 85
Complex vessel (yes vs. no) −5 62 116
Multi vessel disease (yes vs. no) 122 98 200
Diabetes (yes vs. no) −217* 150 78
Post MI (yes vs. no) −88 25 88
Elective (yes vs. no) 346* 208 109
High risk (yes vs. no) −291 127 193
Intervention
Type DES 437
Sirolimus eluting stent 551 100 636
Paclitaxel eluting stent 379 180 636
Zotarolimus eluting stent −324 3 1321
Drug eluting stent in general ref 154
Study characteristics
Country 437
United Kingdom 2147* 211 836
United States 4425* 4 1050
Canada 2922* 79 808
Sweden 1745 39 1016
Brazil 3444* 5 932
Austria 1752 6 1035
Finland 2051 1 1174
Belgium 1698 82 879
Italy ref 10
Study year −190 437 137
Horizon >1 year (yes vs. no) −479 437 277
Horizon (months) b −32* 414 6
Type of study (CUA vs. CEA) −194* 507 86
Model 437
Markov model 613 230 611
Discrete event simulation model −435 6 1219
Decision tree ref 201
Perspective 437
Health care provider perspective 266 14 363
Health care sector perspective −1332 31 1151
Non-public perspective −1057 2 670
Health care payer perspective ref 390
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Table 5 Associations between incremental costs and covariates – DES vs BMSa (Continued)
Funding 347
No 1480* 31 634
Yes 316
Both Industry and No industry 1246 11 1041
Industry −621 56 663
No industry ref 249
Discounting (yes vs. no)c 1071 91 713
Input parameters
Number of stents used during the procedure 708* 424 83
Price difference between stents 1.264* 418 0.13
Price of BMS stent 0.503* 320 0.354
Price of DES stent 1.001* 312 0.152
Costs of BMS procedure (incl. stents) 0.339* 278 0.092
Costs of DES procedure (incl. stents) 0.412* 278 0.053
Difference in procedure costs 0.799* 278 0.075
Probability of restenosis BMS −3072* 407 322
Probability of restenosis DES −1907* 323 899
Relative risk reduction repeat revascularization −1676* 341 250
Disutility of undergoing a CABG NA NA NA
Disutility of undergoing a PCI NA NA NA
Disutility of experiencing a MI NA NA NA
Disutility for a patient with angina symptoms NA NA NA
Quality of life of a patient with angina symptoms NA NA NA
Quality of life of a patient after revascularization (recovered) NA NA NA
Quality of life of a patient suffering from restenosis NA NA NA
Assumptions
Difference in clopidogrel (medication) usage (yes vs. no) 181 279 216
Wait time for revascularization included (yes vs. no) −733 347 486
Repeat revascularization is based on angiographic follow-up data (yes vs. no) −593 372 492
DES and BMS are not mixed up during a procedure −542 437 741
Repeat interventions that occur during time horizon are the result of restenosis 855 437 841
There do not exist differences in mortality, thrombosis or MI between DES and BMS −980 437 878
The type of repeat revascularization is the same for the DES and BMS treatment groups 501 437 1187
There does not exist a difference in survival between DES and BMS −238 437 426
There does not exist a difference in thrombosis between DES and BMS −589 437 754
There does not exist a difference in MI between DES and BMS −595 437 665
Quality of studies (Philips et al. 2006) [7]
Structure (%) 2154 437 1819
Data (%) 1670 437 1318
Consistency (%) 718 437 1463
Total (%) 2761 437 1804
a Corrected for study; bShrive et al. & Remak et al. [17, 20] not included (lifetime horizon); c only studies with a time horizon longer than 1 year included; *
p value < 0.05
CEA cost effectiveness analysis, CUA cost utility analysis, DES drug eluting stent, MI myocardial infarction, NA not applicable, BMS bare metal stent, CABG coronary
artery bypass graft, DES drug eluting stent, MI myocardial infarction, NA not applicable, PCI percutaneous coronary intervention
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study characteristics, input parameters and outcomes.
However, it is not possible to statistically determine if
the association actually exists, which covariates explains
the variation best, to correct for interactions or to pre-
dict the incremental outcomes. This case study was
inspired by meta-analyses of treatment effectiveness
studies that are frequently performed to obtain a single
summary estimate. More interesting than meta-analyses
are meta-regression analyses that try to relate the size of
treatment effect to one or more characteristics of the in-
cluded studies [1]. Using meta-regression analyses to ex-
plore the associations between incremental outcomes
and input parameters is unique for a systematic review
of economic evaluations and could help to explain vari-
ation in cost-effectiveness outcomes between studies.
We used meta-regression analyses to explain the vari-
ability in the outcomes of cost-effectiveness studies (i.e.,
incremental costs and effects) of DES versus BMS and
found that, besides confirming associations that could be
predicted from individual studies, associations at a meta-
level also exist, such as an association between outcomes
and the quality of the models.
The most important factors that were associated with
the results were patient characteristics (age, vessel, le-
sion), procedure (type of stent and elective versus non-
elective), specific input parameters (number of stents
per procedure, cost per stent/procedure, restenosis risk
with BMS and the efficacy of DES) and the quality of the
models. Many of these associations had already been re-
ported in the studies themselves, which can be seen as
evidence that the meta-regression produced valid results.
However, besides these previously reported associations,
we also found associations between study outcomes and
the quality of the model, time horizon, efficacy assump-
tions, and funding which could only be identified at a
‘meta level’. Moreover, this review identified an associ-
ation between the incremental costs and absolute risk
reduction in repeat revascularizations on ‘meta-level’
(Fig. 2) showing the added value of meta-regression
analyses.
Some of the associations we found are desirable since
they involve parameters that influence the results and
that can be controlled by clinicians and policymakers.
For example, factors like the costs of a stent are ex-
pected to be associated with the results. Other factors
such as patient characteristics can be changed by means
of patient selection. However, the presence of other as-
sociations such as the quality of the models, assump-
tions, time horizon or funding raises concerns.
Moreover, other parameters were not significantly asso-
ciated with outcomes (e.g., wait time and incremental
costs, or funding and incremental QALYs). These pa-
rameters could have influenced the outcomes but are
undesirable since e.g., funding should not play a role in
the outcomes of the study. It is important for authors to
follow the recommendations of the ISPOR-SMDM task
force for modelling good research practices [27] and the
recommendations based on the Philips et al. checklist
[7] for modelling studies to increase the quality of the
study and generalizability of the results.
Limitations
Despite the fact that the quality of the models was
assessed by two independent reviewers it was difficult to
judge the quality due to subjectivity of the questions;
this problem was been recognized in the past [28]. Fur-
thermore, to provide studies with a score between 0 and
100 % we needed to assume that all questions of the
checklist were equally important. Thus studies could ob-
tain a reasonably high score if less informative/important
questions were fulfilled. In addition, the quality of the
models was based on the documentation of the model
and therefore it is possible that studies that scored low
did not transparently present model details, however the
actual model could be of high quality. Regardless of
these limitations, we found a statistically significant as-
sociation between quality and the outcome repeat
revascularization.
Furthermore, title abstract screening was performed
by one reviewer which could be seen as a limitation of
the study. However, checks of whether the studies in-
cluded in previously published reviews were also identi-
fied with the search, increased the sensitivity of the
search and thereby reduced the chance of missing rele-
vant publications. Full assessment and assessing the
quality of the model using the Philips checklist was per-
formed by two reviewers independently.
Another limitation of our study is that all 508 analyses
were analysed as independent observations even though
in reality these 508 analyses were based on 16 studies.
We have used study identification number as a random
effect in the regression models to address this problem.
In this case study, linear regression models were used
to estimate the associations of study characteristics on
the outcomes (incremental costs, incremental QALYs
and repeat revascularizations avoided) since the number
of observations was large. However, regression models
could be improved by first considering if the dependent
variable (e.g., incremental costs) can best be modelled
using a different function (e.g., gamma).
Moreover, meta-regression analyses (bivariate or
multivariate) help to explain variation in outcomes, how-
ever it also identified associations that were not expected
a priori. For example, type of study was associated with
the incremental costs, which is not logical since the type
of study mainly influences the incremental effects. Co-
variates that are on beforehand implausible (e.g., type of
study and incremental costs) should not be included in
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future meta-regression analyses since it leads to false
positive outcomes.
In addition, transparency in documentation is a major
issue leading to a high frequency of missing values that
made it impossible to perform multivariate analyses with
all of the parameters that were significant in the bivariate
analyses. Consequently, we were unable to: 1) take into ac-
count interaction effects, 2) determine the most influential
covariates, and 3) create a prediction model. A solution
could be to include a smaller number of input parameters
with only common input parameters (e.g., cost of proced-
ure, time horizon etc.). However, this will lead to fewer as-
sociations between outcomes and covariates.
Transparent reporting is crucial in this field and would
solve the problem of missing values for systematic re-
views such as this. A recently published review on the
challenges of modelling the cost-effectiveness of cardio-
vascular disease interventions has recognized the same
problem [29].
Lastly, we did not include the studies published after
January 2012. However, we expect that including newer
studies that met inclusion criteria (i.e., estimating the
cost-effectiveness of DES versus BMS using modelling
methods) do not have an impact on the results of our
case study showing that using meta-regression analyses
could be useful method in addition to conventional sys-
tematic reviews.
To improve this case study lessons can be learned
from meta-regression analyses and meta-analyses that
are performed for the clinical effectiveness of interven-
tions. More specifically, it could provide guidance in
how to handle missing data [30], how to treat study het-
erogeneity, how to include covariate interaction [31]. In
addition, it shows limitations of the methods [1].
Conclusions
This study has showed that meta-regression analyses can
be used to explore relationships between study charac-
teristics and cost-effectiveness outcomes and can draw
from the methodology used in other fields even though
it is not yet fully developed. Compared with conven-
tional review methods or sensitivity analyses of individ-
ual studies meta-regression analyses can be of added
value since it identifies significant associations that could
not be identified before. The quality of the models was
associated with the outcomes of the studies and there-
fore it is important that a quality check is performed be-
fore interpreting the results of the study.
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